Skip to main content
. 2014 Mar 14;10(5):1366–1372. doi: 10.4161/hv.28397

Table 1. Demographic characteristics of the study subjects, by treatment groups.

  Batch 1 Batch 2 Batch 3 Placebo
Immunogenicity analysis cohort n = 1139 n = 1153 n = 1138 n = 3441
     Age (month) 17.4 (8.1) 17.5 (7.9) 17.5 (7.9) 17.6 (8.0)
     Boy 671 (58.9) 677 (58.7) 641 (56.3) 1876 (54.5)
     Height (cm) 80.6 (8.2) 80.7 (8.1) 80.8 (8.1) 80.8 (8.1)
     Weight (kg) 12.2 (2.2) 12.3 (2.2) 12.2 (2.2) 12.2 (2.2)
     BMI (kg/m2) 18.8 (2.4) 18.9 (2.6) 18.8 (2.5) 18.7 (2.3)
Safety analysis cohort n = 1199 n = 1230 n = 1200 n = 3631
     Age (month) 17.4 (8.0) 17.4 (7.9) 17.5 (7.9) 17.4 (8.0)
     Boy 704 (58.7) 725 (58.9) 675 (56.3) 1990 (54.8)
     Height (cm) 80.5 (8.2) 80.6 (8.0) 80.7 (8.1) 80.7 (8.1)
     Weight (kg) 12.2 (2.2) 12.2 (2.2) 12.2 (2.2) 12.2 (2.2)
     BMI (kg/m2) 18.8 (2.4) 18.9 (2.7) 18.8 (2.5) 18.7 (2.3)

Data are mean (SD), and number (%). N, number of subjects; SD, standard deviation; BMI, body mass index.